Kenneth Hoberman, Chief Operating Officer at STEMLINE THERAPEUTICS INC (STML), sold 59,974 shares at $16.82 ($1.0M) on 2018-03-13, disclosed to the SEC on 2018-03-14.
Seasonal sale ($1.0M) by Chief Operating Officer — this insider has traded STML in March in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $17.18 | 13,942 | $240K | 23.3% |
| 2 | $17.18 | 13,942 | $240K | 23.3% |
| 3 | $18.24 | 3,299 | $60K | 5.9% |
| 4 | $18.24 | 3,299 | $60K | 5.9% |
| 5 | $16.82 | 12,746 | $214K | 20.9% |
| 6 | $16.82 | 12,746 |
| $214K |
| 20.9% |
| Total | $17.14 avg | 59,974 | $1.0M | 100% |
| Filing → |
| STML | SELL | 2020-02-28 | $148K | — | Filing → |
| STML | SELL | 2020-01-24 | $311K | — | Filing → |
| STML | SELL | 2020-01-10 | $274K | — | Filing → |